Monday , October 23 2017
Home / Therapies / SGLT-2 Therapy Center / Christophe Arbet-Engels, MD, Q12: Diabetes Drug Efficacy in Different Populations

Christophe Arbet-Engels, MD, Q12: Diabetes Drug Efficacy in Different Populations

Dr. Christophe Arbet-Engels answer the question, “Do the Swiss get diabetes?” and, on a more serious note, explains that they are exploring different options for different patient populations to find the best treatment possible for each individual patient.  

Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

See more SGLT-2 Resources